A real-world study of palbociclib plus endocrine therapy with or without a short course chemotherapy in the first-line treatment of HR-positive HER2-negative metastatic breast cancer

BackgroundTo investigate the efficacy of palbociclib plus endocrine therapy (ET) as the initial treatment compared with post-chemotherapy maintenance therapy in the first-line treatment of hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) meta...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xiangjun Li, Yuhua Song, Meng Lv, Yongmei Wang, Xueqiang Gao, Tianyi Ma, Teng Ma, Changgen Liu, Xinyi Sun, Haibo Wang, Yan Mao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Oncology
Subjects:	metastatic breast cancer palbociclib endocrine treatment cyclin-dependent kinases 4/6 inhibitor chemotherapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1512496/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

A real-world study of palbociclib plus endocrine therapy with or without a short course chemotherapy in the first-line treatment of HR-positive HER2-negative metastatic breast cancer

Similar Items